Prithviraj Bose, MD

Prithviraj Bose, MD, of The University of Texas MD Anderson Cancer Center, and Javier Pinilla Ibarz, MD, PhD, of Moffitt Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest in myeloproliferative neoplasms and chronic lymphocytic leukemia, respectively, from the 2024 ASH Annual Meeting.

Experts discuss how treatments, either monotherapy or combination, may impact the treatment landscape for MF and how they might choose among the new agents.

Panel experts comment on the role of combination therapies in MF and debate if these therapies will be the new standard of care.

Faculty offer insights into the future of PV management as well as unmet needs.

Faculty discuss the best strategies to monitor patients who are receiving treatment of MF as well as commenting on when it might be appropriate to switch therapies.

Expert oncologists provide insights into how they might manage patients who present with anemia and myelofibrosis in their practice.

Overview of the current FDA approved treatment options for the management of myelofibrosis as well as reviewing recent updates from ASH 2023 on the SIMPLIFY and PERSIST trials.

Panel experts comment on the role of transplant in patients with myelofibrosis.

Experts discuss the clinical implications of the MAJIC-PV trial.

Panel experts talk about when to use cytoreductive therapy and which factors influence their treatment selection as well as reviewing how patients with PV are monitored.

Faculty discuss the treatment goals for patients diagnosed with polycythemia vera and review treatment options for managing PV.

Expert oncologists discuss the REVEAL study and provide their thoughts on these data and the impact in clinical practice.

Experts discuss the optimal strategy for NGS testing, which alterations to test for and how to assess for risk when diagnosing and managing patients with polycythemia vera (PV).

Experts explain how polycythemia vera is diagnosed and the typical symptoms a patient may present with.

The hematologic neoplasm systemic mastocytosis is marked by the clonal proliferation of mast cells in the skin, bone marrow, gastrointestinal tract, spleen, and/or liver, caused by an activating KIT mutation in the KIT gene.

Prithviraj Bose, MD, discusses key data on the use of zilurgisertib alone or in combination with ruxolitinib to reduce disease-related anemia in patients with primary or secondary myelofibrosis.

Prithviraj Bose, MD, discusses key data on the ability of pacritinib to reduce splenomegaly and disease symptoms in patients with myelofibrosis across the cytopenic spectrum.

The panel of experts in SM highlight the unmet needs in the clinical care of systemic mastocytosis.

The panel of experts discuss the diagnosis and assessment of chronic myelomonocytic cell leukemia.

Learn more about the epidemiology, diagnosis, and treatment of advanced systemic mastocytosis in this summary from an expert multidisciplinary case-based discussion.

Prithviraj Bose, MD, discusses risk factors associated with essential thrombocythemia.

Prithviraj Bose, MD, discusses current treatment options for essential thrombocythemia.

Prithviraj Bose, MD, discusses novel agents under investigation in essential thrombocythemia.

Prithviraj Bose, MD, discusses management strategies for patients with myelofibrosis who progress on ruxolitinib (Jakafi).

Prithviraj Bose, MD, associate professor in the Department of Leukemia of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses management strategies for patients with myelofibrosis who progress on ruxolitinib (Jakafi).

Prithviraj Bose, MD, discusses the utility of ruxolitinib in patients with myelofibrosis.

Prithviraj Bose, MD, discusses novel agents under investigation in myelofibrosis.

Prithviraj Bose, MD, discusses novel agents under investigation in myelofibrosis.

Prithviraj Bose, MD, discusses treatment for patients with progressive myelofibrosis.